Tonix’s TONMYA Sales Rise 37% — But Its Quarterly Loss Reaches $53.3 Million

Insurance access expanded, while commercialization and research spending climbed and operating cash use increased.

Share
Tonix’s TONMYA Sales Rise 37% — But Its Quarterly Loss Reaches $53.3 Million

Tonix Pharmaceuticals, which sells and develops medicines, reported Monday that TONMYA sales rose 37% from the second quarter, but its third-quarter loss attributable to common shareholders widened to $53.3 million from $32.0 million a year earlier. The results accompanied an SEC filing, with spending on the fibromyalgia drug’s rollout and clinical development climbing.

TONMYA Drives Revenue, Refills Climb

Tonix’s third-quarter product revenue reached approximately $17.2 million, against $3.3 million a year earlier. TONMYA contributed approximately $15.0 million; its acute migraine medicines, Zembrace SymTouch and Tosymra, contributed approximately $2.2 million, down from $3.3 million.

TONMYA, an FDA-approved tablet dissolved under the tongue for adults with fibromyalgia, launched on November 17, 2025. Prescriptions totaled 16,375 in the third quarter, up 28% from the second quarter. New prescriptions increased 17%, and refills increased 56%. The total includes initial fills supplied through Tonix’s digital pharmacy while insurance decisions are pending; those fills produce no immediate net product revenue.

Coverage now reaches approximately 166 million people, roughly 53% of the approximately 314 million covered lives in the U.S. Managed Medicare agreements announced in July and September 2026 added approximately nine million and 21 million lives, respectively.

“This expanded access contributed to third quarter sales growth,” Tonix President and CEO Seth Lederman said in the earnings release.

Tonix added 50 representatives on September 1, 2026, bringing its TONMYA sales force to approximately 150. Thomas Englese was promoted to chief commercial officer on September 8, 2026; he had served as executive vice president for commercial operations since September 2024.

The Rollout’s Larger Spending Bill

Selling and administrative expenses reached approximately $45.6 million, versus $25.7 million a year earlier. The increase primarily came from TONMYA commercialization, including $13.5 million more in sales and marketing costs, $4.1 million more in employee expenses and $1.5 million more in professional expenses.

Research and development spending reached approximately $25.8 million, against $9.3 million. Higher manufacturing expenses accounted for $9.8 million of the increase, clinical expenses for $3.6 million, non-clinical expenses for $1.1 million and employee costs for $1.5 million. Cost of sales fell to approximately $1.3 million from $1.4 million because of a different product mix.

The larger total loss came with a smaller loss per share: $2.89, versus $3.59 a year earlier. Weighted-average shares outstanding were 18,440,773, compared with 8,922,792.

TONMYA also faces a generic patent challenge. On October 2, 2026, Tonix reported receiving notice that Dr. Reddy’s Laboratories had sought FDA approval for a generic version and challenged its patents. Tonix intends to enforce its intellectual property rights, but says it cannot predict the outcome.

Cash Funds The Next Clinical Steps

Tonix held approximately $163 million in cash and cash equivalents at September 30, 2026, compared with approximately $207.6 million at December 31, 2025. Operations consumed approximately $125.6 million during the first nine months of 2026, versus approximately $60.2 million during the same period in 2025.

Management expects that cash, together with approximately $1.5 million in net proceeds from subsequent equity offerings, to cover operations and capital spending into the early third quarter of 2027. Tonix had 19,431,516 common shares outstanding as of Friday.

Clinical priorities include an ongoing mid-stage study testing TNX-102 SL as a stand-alone treatment for adults with major depressive disorder. The six-week study compares the medicine with a placebo.

Tonix expects its mid-stage Lyme disease prevention study of TNX-4800 to begin in the first quarter of 2027, pending final FDA agreement on the protocol. The company says it remains on track to deliver investigational medicine to study sites that quarter.

An investigator-led mid-stage study of TNX-1500 at Massachusetts General Hospital is also expected to begin in the first quarter of 2027, enrolling five adult kidney transplant recipients to test prevention of rejection.

Sources

More on Tonix Pharmaceuticals

All Tonix Pharmaceuticals (TNXP) coverage →